<DOC>
	<DOCNO>NCT02176148</DOCNO>
	<brief_summary>Cutaneous lupus chronic , relapse , auto-immune skin disease many presentation . Its effect physical appearance greatly affect patient ' quality life . In addition , 10 % patient cutaneous lupus develop systemic lupus . Topical therapy mainstay cutaneous lupus treatment ; however patient often find treatment messy , inconvenient , ineffective . In addition , severe disease patient often place concurrent systemic therapy . The primary hypothesis study poor adherence contributes poor treatment outcomes patient cutaneous lupus .</brief_summary>
	<brief_title>Cutaneous Lupus Medication Experience Study</brief_title>
	<detailed_description>Cutaneous lupus chronic , relapse auto-immune disease negatively impact patient ' quality life . As many safe topical therapy require daily use effective , adherence medication remain common problem dermatology , worthwhile reliably measure adherence medication patient cutaneous lupus . By elucidate barrier effective control cutaneous lupus topical medication , improve patient care guide intervention avoid use systemic therapy often side effect . The primary aim determine adherence topical systemic lupus treatment . Subjects receive standard care therapy ( low potency high potency topical corticosteroid ) systemic therapy clinically appropriate . Adherence medication monitor electronically subject . The following hypothesis test : Non-adherence topical systemic medication contributes treatment failure patient cutaneous lupus .</detailed_description>
	<mesh_term>Fluocinonide</mesh_term>
	<criteria>Any male female 12 year old age diagnosis cutaneous lupus dermatologist Capable understanding willing provide sign dated write voluntary informed consent protocol specific procedure perform Able complete study comply study instruction , include attend study visit Individuals young 12 year age Known allergy sensitivity study medication Inability complete studyrelated visit Introduction prescription medication , topical systemic , cutaneous lupus participate study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cutaneous lupus</keyword>
	<keyword>systemic lupus</keyword>
	<keyword>systemic therapy</keyword>
	<keyword>medication</keyword>
</DOC>